Business Context and Reporting Period
This Form 8-K was filed by LabStyle Innovations Corp. (referred to in metadata as Dariohealth Corp.) on August 28, 2015. The report details the second closing of a private placement offering (the "Offering") to fund the global penetration and initial U.S. commercial launch of the Company's Dario™ product, a mobile, cloud-based diabetes management solution.
Key Financial Metrics
- Proceeds from Second Closing: Approximately $962,102 in gross proceeds.
- Total Offering Proceeds: Approximately $2,505,261 (including the initial closing on July 23, 2015).
- Units Sold in Second Closing: 3,207,007 Units.
- Purchase Price: $0.30 per Unit.
- Securities Issued (Second Closing): 3,207,007 shares of Common Stock and Warrants exercisable for 3,207,010 shares of Common Stock.
- Placement Agent Compensation: Aggregate commission of $94,391 (with $3,210 payable at this closing), 50,000 restricted shares, and 898,313 Placement Agent Warrants.
- Finders' Compensation (Second Closing): 619,605 restricted shares and 619,606 Finders' Warrants.
Material Changes
The primary material change is the completion of the second tranche of the private placement offering. This transaction increased the Company's cash reserves by approximately $962,102 and significantly expanded the outstanding share count and warrant pool. The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the period; it focuses exclusively on the capital raise event.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds are designated for the global penetration and U.S. commercial launch of the Dario™ product and for working capital purposes.
- Warrant Terms:
- Series A Warrants: Exercise price of $0.35, expire 12 months from issuance.
- Series B Warrants: Exercise price of $0.40, expire 36 months from issuance.
- Registration Obligations: The Company agreed to file a registration statement for resale of shares and warrant-issuable shares within 60 days of the initial closing and use reasonable best efforts to have it declared effective within 75 days (or 150 days if reviewed by the SEC).
- Risks: The filing includes a standard cautionary note regarding forward-looking statements, noting that actual results may differ materially due to risks discussed in other SEC filings. The securities issued are unregistered and cannot be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-closing to assess dilution impact.
- Confirm the status of the registration statement for the resale of securities (filed within 60 days of July 23, 2015).
- Review the Company's cash burn rate and runway given the stated use of proceeds for commercial launch.
- Check for any subsequent filings regarding the effectiveness of the registration statement or changes in the Offering terms.
- Validate the identity of the "Investors" and the extent of institutional versus retail participation.